公开(公告)号：US20210338765A1

公开(公告)日：2021-11-04

申请号：US17306937

申请日：2021-05-03

申请人： Bioved Pharmaceuticals, Inc.

发明人： DEEPA CHITRE ,  DEBENDRANATH DEY ,  SATEJ R. NADKARNI

IPC分类号： A61K36/9066 ,  A61K36/268 ,  A61K36/324 ,  A61K45/06 ,  A61K31/375 ,  A61K31/315 ,  A61K31/197 ,  A61K31/25

摘要： Methods and compounds for preventing and arresting COVID-19 morbidity and mortality, via inhibition of Interleukin-6, TNF-alpha, and other cytokines, and via reduction of C-reactive proteins are provided. Analyses of patients with COVID-19 complicated by ARDS, for example, show highly activated cytotoxic T-cells, resulting from hyperactivation of the immune system. A significant surge of Interleukin-6 (IL-6), TNF-α, and other cytokines are thought to be mediators of this enhanced T-cell activity, and runaway inflammation that are dangerous or fatal to the patient. Example oral formulations dubbed BV-4051 and Artovid-20 provide prophylaxis and treatment of these conditions caused by COVID-19 disease. The example formulations contain plant extracts boosting the human immune system and targeting the detrimental effects of the SARS-CoV-2 virus in its various strains.